Pathology/Immunology Core

佛罗里达大学分子病理学和免疫学核心目前协助 参与旨在提高对1型肺炎发病机制理解的项目的研究人员 糖尿病，以及能够逆转和/或预防这种疾病的药物的开发。 具体地说，核心通过进行病理和免疫学分析来支持这些调查 宿主的免疫系统和细胞/组织反应的特征，包括涉及治疗的那些 建议的或目前用于实验和临床前研究的。这一目标过去是，也将继续是 通过实现以下三个具体目标来实现：1)在以下情况下确定组织形态 组织病理学，以评估治疗效果的给药部位，剂量和治疗 持续时间。2)确定治疗糖尿病小鼠模型的潜在有益效果； 评估胰腺和其他与1型糖尿病相关的器官。3)进行免疫学 在动物模型和人类受试者中的评价，表征与体液和 细胞免疫反应，以及提供1型糖尿病的遗传易感性。形态上的 研究对于评估特定项目的干预是否成功地改善亲和力至关重要。 胰腺、淋巴结、脾和其他器官内的炎症环境，并确定 任何干预措施引起急性炎症或细胞毒性的程度。集中管理 形态研究和组织病理学和毒理学决定因素的标准化，使 对细胞反应的严格评估。程序包括石蜡和冰冻切片的标准组织学 材料、特殊染色、组织化学、免疫组织化学和免疫荧光。就.而言 对于人体样本的分析，核心实验室将建立在20多年的经验基础上 1型高危或高危患者血清中自身抗体存在的评估术语 糖尿病，以及通过表现的人类白细胞抗原配型来确定疾病的遗传易感性。在……里面 除了为确保治疗安全性和改进机制提供关键要素之外 理解，核心应提供信息，以加强临床前治疗的可行性和有效性 预防或逆转1型糖尿病的试验。

The Molecular Pathology and Immunology Core of the University of Florida currently assists multiple investigators participating in Projects aimed at an improved understanding of the pathogenesis of type 1 diabetes, as well as the development of agents capable of reversing and/or preventing the disease. Specifically, the Core supports these investigations by performing pathological and immunological analyses that characterize the host's immune system and cell/tissue response, including those involving treatments proposed or currently used in experimental and preclinical studies. This goal has and will continue to be accomplished by performance of three specific aims: 1) Determine tissue morphology in the context of histopathology in order to evaluate treatment effects with respect to administration site, dose, and treatment duration. 2) Determine the potential beneficial effects of treatments in murine models of diabetes; with assessment of the pancreas as well other organs related to type 1 diabetes. 3) Perform immunologic evaluations in animal models and human subjects that characterize aspects related to the humoral and cellular immune response, as well as providing genetic susceptibility to type 1 diabetes. The morphological studies are vital in order to evaluate whether a given Project's intervention successfully ameliorates the pro- inflammatory environment within the pancreas, lymph node, spleen, and other organs and to determine the extent to which any intervention induces acute inflammation or cytotoxicity. Centralization of the morphological studies, and standardization of the histopathological and toxicological determinants, enables rigorous assessment of cellular responses. Procedures include standard histology on paraffin and frozen materials, special stains, histochemistry, immunohistochemistry, and immunofluorescence. In terms of analysis of human samples, the Core laboratory will build upon more that two decades of experience in terms of evaluating for the presence of autoantibodies in serum of patients with or at increased-risk of type 1 diabetes, as well as determining the genetic susceptibility for the disease by performance of HLA typing. In addition to providing a critical element for assurance of therapeutic safety and improved mechanistic understanding, the Core should provide information that will enhance the feasibility and efficacy of preclinical trials to prevent or reverse type 1 diabetes.